1. Non-coding RNAs underlying chemoresistance in gastric cancer.
- Author
-
Poursheikhani, A, Bahmanpour, Z, Razmara, E, Mashouri, L, Taheri, M, Morshedi Rad, D, Yousefi, H, Bitaraf, A, Babashah, S, Poursheikhani, A, Bahmanpour, Z, Razmara, E, Mashouri, L, Taheri, M, Morshedi Rad, D, Yousefi, H, Bitaraf, A, and Babashah, S
- Abstract
Background
Gastric cancer (GC) is a major health issue in the Western world. Current clinical imperatives for this disease include the identification of more effective biomarkers to detect GC at early stages and enhance the prevention and treatment of metastatic and chemoresistant GC. The advent of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long-non coding RNAs (lncRNAs), has led to a better understanding of the mechanisms by which GC cells acquire features of therapy resistance. ncRNAs play critical roles in normal physiology, but their dysregulation has been detected in a variety of cancers, including GC. A subset of ncRNAs is GC-specific, implying their potential application as biomarkers and/or therapeutic targets. Hence, evaluating the specific functions of ncRNAs will help to expand novel treatment options for GC.Conclusions
In this review, we summarize some of the well-known ncRNAs that play a role in the development and progression of GC. We also review the application of such ncRNAs in clinical diagnostics and trials as potential biomarkers. Obviously, a deeper understanding of the biology and function of ncRNAs underlying chemoresistance can broaden horizons toward the development of personalized therapy against GC.- Published
- 2020